Loading...
XSHE
300453
Market cap705mUSD
Sep 30, Last price  
9.05CNY
Name

Jiangxi Sanxin Medtec Co Ltd

Chart & performance

D1W1MN
XSHE:300453 chart
P/E
17.83
P/S
2.88
EPS
0.51
Div yield, %
3.31%
Shrs. gr., 5y
0.15%
Rev. gr., 5y
7.09%
Revenues
1.64b
+9.31%
220,401,905280,442,903304,737,397322,204,633311,848,211317,774,431403,871,872531,302,358721,668,064940,385,5881,164,288,7631,164,288,7631,336,002,6471,336,002,6461,300,060,9801,500,438,4161,640,093,700
Net income
265m
+16.51%
35,026,82147,697,58048,642,66448,615,38851,876,40336,613,95842,389,56241,145,67661,683,111115,624,850155,910,663155,910,666184,634,263184,634,263206,633,861227,404,093264,937,745
CFO
461m
+18.23%
34,434,00041,264,88130,005,64768,291,52262,880,19061,303,42162,262,10058,886,773167,355,013272,895,487329,716,957402,176,397346,149,480389,586,619460,599,948
Dividend
Sep 23, 20260.10024 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Nanchang, China, in 1997, Jiangxi Sanxin Medtec Co., Ltd. is a medical technology company dedicated to the research, development, manufacturing, sales, and servicing of medical devices. The company operates both domestically and internationally, offering a wide array of products across several key therapeutic categories: Renal Dialysis and Blood Purification: This segment includes advanced centralized dialysate supply systems, hemodialysis water preparation units, and hemodialysis machines. It also provides a variety of consumables such as specialized nursing kits, central venous catheter packs, arteriovenous spikes, HDF accessory tubing, dialysate filters, hemodialysis powders and concentrates, hollow fiber hemodialyzers, sterile blood circuits, and tubing sets for hemodialysis. Infusion and Transfusion Equipment: The company supplies various infusion and transfusion sets, including light-resistant, TPE precise filter, and auto-stop fluid precise filter types, alongside standard transfusion sets, catheter infusion sets, and precise filter light-resistant options. Injection Devices: Its portfolio encompasses diverse syringes, such as insulin, dispenser, sterile, auto-disable, and fixed-dose immunization syringes. This category also features hypodermic needles, innovative needleless injection systems, and pneumatic syringes. Intravenous Catheterization Products: Offerings include various indwelling catheters like straight, Y-type, and closed IV catheters, positive pressure IV catheters, central venous catheter kits, extension tubes with three-way valves, and heparin caps. General Medical Supplies: Additional products include blood microembolus filters, disposable extracorporeal circulation tubing kits, cold cardioplegic solution perfusion apparatus, blood containers, medical-grade surgical masks, disinfectants, and alcohol pads.

Key people

Yixing Peng
Chairman of the Board
Zhiping Mao
President, Director · since 2023
Lingli Leng
Vice President · since 2023
Bingrong Liu
Vice President · since 2023
Ling Peng
Vice President · since 2023
Ganying Wang
Vice President · since 2023
Zhenrong Le
Director · since 2023
Fenglian Lei
Vice Chairman of the Board · since 2020
Ming Liu
Acting Chief Financial Officer, Vice President, Secretary of the Board, Director · since 2024
Independent Director · since 2023
Haihong Jiang
Independent Director
Dongjing Liu
Independent Director · since 2025
Xiaohua Xia
Independent Director · since 2023
IPO date
May 15, 2015
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
江西省南昌县小蓝经济开发区富山大道999号
南昌市, JX 330200
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT